Antares Pharma Company Profile (NASDAQ:ATRS)

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ATRS
  • CUSIP: 03664210
  • Web: www.antarespharma.com
Capitalization:
  • Market Cap: $395.8 million
  • Outstanding Shares: 155,214,000
Average Prices:
  • 50 Day Moving Avg: $2.82
  • 200 Day Moving Avg: $2.42
  • 52 Week Range: $0.88 - $3.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 127.50
  • P/E Growth: -0.26
Sales & Book Value:
  • Annual Revenue: $51.91 million
  • Price / Sales: 7.62
  • Book Value: $0.27 per share
  • Price / Book: 9.44
Profitability:
  • EBIDTA: ($19,260,000.00)
  • Net Margins: -53.11%
  • Return on Equity: -45.93%
  • Return on Assets: -33.43%
Debt:
  • Current Ratio: 2.40%
  • Quick Ratio: 2.08%
Misc:
  • Average Volume: 1.35 million shs.
  • Beta: 0.88
  • Short Ratio: 2.39
 

Frequently Asked Questions for Antares Pharma (NASDAQ:ATRS)

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) posted its earnings results on Tuesday, May, 9th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The firm earned $12.01 million during the quarter, compared to analysts' expectations of $12.10 million. Antares Pharma had a negative net margin of 53.11% and a negative return on equity of 45.93%. View Antares Pharma's Earnings History.

Where is Antares Pharma's stock going? Where will Antares Pharma's stock price be in 2017?

2 brokers have issued 1 year price objectives for Antares Pharma's shares. Their forecasts range from $2.00 to $4.30. On average, they anticipate Antares Pharma's share price to reach $3.15 in the next twelve months. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who owns Antares Pharma stock?

Antares Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (4.92%), Vanguard Group Inc. (0.00%), Renaissance Technologies LLC (0.00%), Perceptive Advisors LLC (1.88%), Rubric Capital Management LP (1.53%) and Kingdon Capital Management L.L.C. (1.16%). Company insiders that own Antares Pharma stock include Fred M Powell, James E Fickenscher, James E Flynn, Leonard S Jacob, Peter J Graham, Robert F Apple, Robert P Roche Jr and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Who sold Antares Pharma stock? Who is selling Antares Pharma stock?

Antares Pharma's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Kingdon Capital Management L.L.C., Oppenheimer & Co. Inc., Perkins Capital Management Inc. and Baird Financial Group Inc.. Company insiders that have sold Antares Pharma stock in the last year include Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Who bought Antares Pharma stock? Who is buying Antares Pharma stock?

Antares Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Morgan Stanley, Laurion Capital Management LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, EAM Investors LLC, Vanguard Group Inc. and Segantii Capital Management Ltd. Company insiders that have bought Antares Pharma stock in the last two years include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham, Robert F Apple and Robert P Roche Jr. View Insider Buying and Selling for Antares Pharma.

How do I buy Antares Pharma stock?

Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Antares Pharma stock cost?

One share of Antares Pharma stock can currently be purchased for approximately $2.55.

Analyst Ratings

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (?)
Ratings Breakdown: 1 Buy Rating, 1 Strong Buy Rating
Consensus Rating:Strong Buy (Score: 3.50)
Consensus Price Target: $3.15 (23.53% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Raymond James Financial, Inc.Initiated CoverageStrong-Buy$4.30LowView Rating Details
8/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$3.00 -> $2.00N/AView Rating Details
5/10/2016Jefferies Group LLCReiterated RatingBuy$3.00N/AView Rating Details
9/25/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$4.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Antares Pharma (NASDAQ:ATRS)
Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)
Earnings History by Quarter for Antares Pharma (NASDAQ:ATRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.04)($0.03)$12.10 million$12.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.04)($0.03)$12.77 million$14.20 millionViewN/AView Earnings Details
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)$10.14 million$11.09 millionViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.07)($0.05)$6.92 million$6.57 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Antares Pharma (NASDAQ:ATRS)
2017 EPS Consensus Estimate: ($0.15)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20172($0.03)($0.03)($0.03)
Q3 20172($0.04)($0.02)($0.03)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Antares Pharma (NASDAQ:ATRS)
Insider Ownership Percentage: 10.77%
Institutional Ownership Percentage: 33.60%
Insider Trades by Quarter for Antares Pharma (NASDAQ:ATRS)
Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)
Insider Trades by Quarter for Antares Pharma (NASDAQ:ATRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/5/2017Robert F AppleCEOSell40,000$3.00$120,000.00View SEC Filing  
4/4/2017Leonard S JacobDirectorSell41,762$2.89$120,692.18View SEC Filing  
4/4/2017Robert F AppleCEOSell37,000$3.00$111,000.00View SEC Filing  
4/3/2017Leonard S JacobDirectorSell20,000$2.88$57,600.00View SEC Filing  
3/31/2017Thomas J GarrityDirectorSell30,000$2.91$87,300.00View SEC Filing  
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Antares Pharma (NASDAQ:ATRS)
Latest Headlines for Antares Pharma (NASDAQ:ATRS)
Source:
DateHeadline
finance.yahoo.com logoATRS: Milestones Continue to Align for Multiple 2018 Launches
finance.yahoo.com - May 16 at 8:48 PM
nasdaq.com logoAntares Pharma Announces Poster Presentation at the American Urological Association Annual Meeting - Nasdaq
www.nasdaq.com - May 16 at 3:47 PM
finance.yahoo.com logoAntares Pharma Announces Poster Presentation at the American Urological Association Annual Meeting
finance.yahoo.com - May 16 at 12:29 PM
americanbankingnews.com logoBrokers Issue Forecasts for Antares Pharma Inc's FY2017 Earnings (ATRS)
www.americanbankingnews.com - May 15 at 8:52 AM
americanbankingnews.com logoAntares Pharma Inc to Post FY2017 Earnings of ($0.14) Per Share, Jefferies Group Forecasts (ATRS)
www.americanbankingnews.com - May 12 at 1:18 PM
americanbankingnews.com logoBrokers Issue Forecasts for Antares Pharma Inc's Q2 2017 Earnings (ATRS)
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 10 at 10:22 PM
streetinsider.com logoAntares Pharma (ATRS) Reports In-Line Q1 EPS - StreetInsider.com
www.streetinsider.com - May 10 at 9:04 AM
nasdaq.com logoAntares Pharma Q1 Loss Narrows
www.nasdaq.com - May 9 at 8:44 PM
finance.yahoo.com logoEdited Transcript of ATRS earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 9 at 8:44 PM
streetinsider.com logoAntares Pharma (ATRS) Reports In-Line Q1 EPS
www.streetinsider.com - May 9 at 3:42 PM
finance.yahoo.com logoAntares Pharma Reports First Quarter 2017 Operating and Financial Results
finance.yahoo.com - May 9 at 9:05 AM
finance.yahoo.com logoAntares Pharma reports 1Q loss
finance.yahoo.com - May 9 at 9:05 AM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:12 PM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 10:47 PM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 10:23 PM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Expected to Announce Quarterly Sales of $12.1 Million
www.americanbankingnews.com - May 5 at 3:54 PM
prnewswire.com logoResearch Reports Coverage on Medical Supplies Stocks -- Antares Pharma, Becton, Dickinson, Integra LifeSciences ... - PR Newswire (press release)
www.prnewswire.com - May 5 at 3:44 PM
americanbankingnews.com logoAntares Pharma (ATRS) Receiving Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 7:28 PM
americanbankingnews.com logoZacks: Brokerages Expect Antares Pharma Inc (ATRS) Will Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - May 3 at 8:12 AM
globenewswire.com logoAntares Pharma to Report First Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call - GlobeNewswire (press release)
www.globenewswire.com - May 2 at 3:46 PM
feeds.benzinga.com logoAntares Pharma to Report First Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
feeds.benzinga.com - May 2 at 7:43 AM
finance.yahoo.com logoAntares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
finance.yahoo.com - April 27 at 4:06 PM
feeds.benzinga.com logoAntares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
feeds.benzinga.com - April 27 at 8:08 AM
americanbankingnews.com logoFavorable Media Coverage Somewhat Likely to Affect Antares Pharma (ATRS) Share Price
www.americanbankingnews.com - April 26 at 4:54 PM
finance.yahoo.com logoDon't Be Surprised If Dip Buyers Jump In on Any Pullback
finance.yahoo.com - April 26 at 4:01 PM
finance.yahoo.com logoETFs with exposure to Antares Pharma, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 3:40 PM
americanbankingnews.com logoAntares Pharma (ATRS) Earning Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 21 at 10:49 AM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Earns Strong-Buy Rating from Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - April 20 at 6:59 PM
finance.yahoo.com logoAMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
finance.yahoo.com - April 17 at 9:41 AM
americanbankingnews.com logoShort Interest in Antares Pharma Inc (ATRS) Rises By 8.0%
www.americanbankingnews.com - April 8 at 7:06 AM
finance.yahoo.com logoETFs with exposure to Antares Pharma, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:45 PM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Director Leonard S. Jacob Sells 20,000 Shares
www.americanbankingnews.com - April 5 at 11:15 PM
americanbankingnews.com logoAntares Pharma Inc (ATRS) CEO Robert F. Apple Sells 37,000 Shares
www.americanbankingnews.com - April 5 at 11:12 PM
americanbankingnews.com logoRobert F. Apple Sells 40,000 Shares of Antares Pharma Inc (ATRS) Stock
www.americanbankingnews.com - April 5 at 8:55 PM
americanbankingnews.com logoLeonard S. Jacob Sells 41,762 Shares of Antares Pharma Inc (ATRS) Stock
www.americanbankingnews.com - April 5 at 8:55 PM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Director Thomas J. Garrity Sells 30,000 Shares
www.americanbankingnews.com - April 4 at 8:58 PM
finance.yahoo.com logoAntares Pharma Announces Poster Presentation of Quickshot Testosterone Data at the Endocrine Society Annual Meeting
finance.yahoo.com - April 3 at 4:05 PM
americanbankingnews.com logoFY2019 EPS Estimates for Antares Pharma Inc (ATRS) Decreased by Analyst
www.americanbankingnews.com - April 3 at 12:54 PM
us.rd.yahoo.com logoPenny Stocks to Watch for April 2017 (ATRS, WRN)
us.rd.yahoo.com - March 31 at 3:51 PM
finance.yahoo.com logoATRS: 2016 Financial and Operational Results
finance.yahoo.com - March 21 at 12:32 PM
finance.yahoo.com logoANTARES PHARMA, INC. Financials
finance.yahoo.com - March 18 at 3:37 PM
rttnews.com logoAntares Pharma Posts Narrower Loss In Q4 - Quick Facts
www.rttnews.com - March 14 at 3:37 PM
nasdaq.com logoAntares Pharma Posts Narrower Loss In Q4 - Quick Facts
www.nasdaq.com - March 14 at 3:37 PM
us.rd.yahoo.com logoAntares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results
us.rd.yahoo.com - March 14 at 3:37 PM
us.rd.yahoo.com logoAntares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results
us.rd.yahoo.com - March 14 at 3:37 PM
biz.yahoo.com logoANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
us.rd.yahoo.com - March 14 at 3:37 PM
biz.yahoo.com logoANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
us.rd.yahoo.com - March 14 at 3:37 PM
us.rd.yahoo.com logo7:04 am Antares Pharma reports Q4 results
us.rd.yahoo.com - March 14 at 3:37 PM
us.rd.yahoo.com logo7:04 am Antares Pharma reports Q4 results
us.rd.yahoo.com - March 14 at 3:37 PM

Social

Chart

Antares Pharma (ATRS) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff